Loading…
Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023
Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved R...
Saved in:
| Published in: | MMWR. Morbidity and mortality weekly report 2023-10, Vol.72 (41), p.1115-1122 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73 |
| container_end_page | 1122 |
| container_issue | 41 |
| container_start_page | 1115 |
| container_title | MMWR. Morbidity and mortality weekly report |
| container_volume | 72 |
| creator | Fleming-Dutra, Katherine E Jones, Jefferson M Roper, Lauren E Prill, Mila M Ortega-Sanchez, Ismael R Moulia, Danielle L Wallace, Megan Godfrey, Monica Broder, Karen R Tepper, Naomi K Brooks, Oliver Sánchez, Pablo J Kotton, Camille N Mahon, Barbara E Long, Sarah S McMorrow, Meredith L |
| description | Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged |
| doi_str_mv | 10.15585/mmwr.mm7241e1 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578951</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A769277086</galeid><sourcerecordid>A769277086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73</originalsourceid><addsrcrecordid>eNp9k91v0zAUxQMCsTJ45RFZQ0I8kGLH-XB4QVXHx6RKTGydeIsc57o1SuxiO526vx6nXadtqnAeLOX-zjk3N7pR9IbgMckyln3qums77roiSQmQp9GIZGkWs5z8fhaNMEnLOCFldhS9dO4PHg7FL6IjWrAkTRM6ejKaO0BGIr8EdC7VDVj0C9xKWe6N3aCLjRYbr3iLrpTtHbriQigN6LS3Si_QuYWF5gFB0tidh4U1aK-MHlz_YxVPnDNCcQ8NmpnrR7mXlguPTpUDHvpTGp1pybV3nwMlTNeBbvgQ4va9T5q1coNyGqrKewhfFVRd12t1s0VDa8FTCXAoRnOthuALH_LdR5TghL6KnkveOnh9ex9H829fL6c_4tnP72fTySwWaV6SmNS5pCnjEnDJmawbyXlNilrUNKWMNilOS8AZx6SUQPNaJhynUhSFxAnLZEGPoy8731Vfd9CIMC3L22plVcftpjJcVQ8rWi2rhVlXBGcFKzMSHE5uHaz524PzlYWVsd5VCSsYJTkpywB9eAR1ygloW67B9Fu0oAxnePB7t0MXvIVKaWlCrhjwalLkZVIUmOWBig9QC9AQmjQapAqvH_DjA3x4GuiUOCh4f0-wBN76pTNtv_3PB52FNc5ZkHfDI7jabkU1bEW134ogeHt_5Hf4fg3oPwWZDec</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2878316199</pqid></control><display><type>article</type><title>Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023</title><source>Open Access: PubMed Central</source><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><creator>Fleming-Dutra, Katherine E ; Jones, Jefferson M ; Roper, Lauren E ; Prill, Mila M ; Ortega-Sanchez, Ismael R ; Moulia, Danielle L ; Wallace, Megan ; Godfrey, Monica ; Broder, Karen R ; Tepper, Naomi K ; Brooks, Oliver ; Sánchez, Pablo J ; Kotton, Camille N ; Mahon, Barbara E ; Long, Sarah S ; McMorrow, Meredith L</creator><creatorcontrib>Fleming-Dutra, Katherine E ; Jones, Jefferson M ; Roper, Lauren E ; Prill, Mila M ; Ortega-Sanchez, Ismael R ; Moulia, Danielle L ; Wallace, Megan ; Godfrey, Monica ; Broder, Karen R ; Tepper, Naomi K ; Brooks, Oliver ; Sánchez, Pablo J ; Kotton, Camille N ; Mahon, Barbara E ; Long, Sarah S ; McMorrow, Meredith L</creatorcontrib><description>Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.</description><identifier>ISSN: 0149-2195</identifier><identifier>EISSN: 1545-861X</identifier><identifier>DOI: 10.15585/mmwr.mm7241e1</identifier><identifier>PMID: 37824423</identifier><language>eng</language><publisher>United States: U.S. Government Printing Office</publisher><subject>Advisory Committees ; Communicable Diseases ; COVID-19 vaccines ; Disease prevention ; Disease transmission ; Diseases ; Drug approval ; Drug dosages ; Economic impact ; Epidemiology ; FDA approval ; Female ; France ; Full Report ; Gestation ; Hospitalization ; Humans ; Hypertension ; Immunization ; Infant ; Infants ; Pandemics ; Pediatrics ; Pharmaceutical industry ; Preeclampsia ; Pregnancy ; Pregnant women ; Premature birth ; Prevention ; Public health ; Respiratory syncytial virus ; Respiratory Syncytial Virus Infections - epidemiology ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory Syncytial Virus Vaccines ; Respiratory Syncytial Virus, Human ; Respiratory tract ; Respiratory tract diseases ; Respiratory tract infection ; Respiratory Tract Infections - epidemiology ; Respiratory Tract Infections - prevention & control ; Seasons ; United Kingdom ; United States ; United States - epidemiology ; Vaccination ; Vaccines ; Viruses</subject><ispartof>MMWR. Morbidity and mortality weekly report, 2023-10, Vol.72 (41), p.1115-1122</ispartof><rights>COPYRIGHT 2023 U.S. Government Printing Office</rights><rights>Published 2023. This article is a U.S. Government work and is in the public domain in the USA.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73</citedby><cites>FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578951/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2878316199?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,315,733,786,790,891,21542,27957,27958,33647,33649,43768,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37824423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Jones, Jefferson M</creatorcontrib><creatorcontrib>Roper, Lauren E</creatorcontrib><creatorcontrib>Prill, Mila M</creatorcontrib><creatorcontrib>Ortega-Sanchez, Ismael R</creatorcontrib><creatorcontrib>Moulia, Danielle L</creatorcontrib><creatorcontrib>Wallace, Megan</creatorcontrib><creatorcontrib>Godfrey, Monica</creatorcontrib><creatorcontrib>Broder, Karen R</creatorcontrib><creatorcontrib>Tepper, Naomi K</creatorcontrib><creatorcontrib>Brooks, Oliver</creatorcontrib><creatorcontrib>Sánchez, Pablo J</creatorcontrib><creatorcontrib>Kotton, Camille N</creatorcontrib><creatorcontrib>Mahon, Barbara E</creatorcontrib><creatorcontrib>Long, Sarah S</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><title>Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023</title><title>MMWR. Morbidity and mortality weekly report</title><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><description>Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.</description><subject>Advisory Committees</subject><subject>Communicable Diseases</subject><subject>COVID-19 vaccines</subject><subject>Disease prevention</subject><subject>Disease transmission</subject><subject>Diseases</subject><subject>Drug approval</subject><subject>Drug dosages</subject><subject>Economic impact</subject><subject>Epidemiology</subject><subject>FDA approval</subject><subject>Female</subject><subject>France</subject><subject>Full Report</subject><subject>Gestation</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Immunization</subject><subject>Infant</subject><subject>Infants</subject><subject>Pandemics</subject><subject>Pediatrics</subject><subject>Pharmaceutical industry</subject><subject>Preeclampsia</subject><subject>Pregnancy</subject><subject>Pregnant women</subject><subject>Premature birth</subject><subject>Prevention</subject><subject>Public health</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory Syncytial Virus Infections - epidemiology</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory Syncytial Virus Vaccines</subject><subject>Respiratory Syncytial Virus, Human</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Respiratory tract infection</subject><subject>Respiratory Tract Infections - epidemiology</subject><subject>Respiratory Tract Infections - prevention & control</subject><subject>Seasons</subject><subject>United Kingdom</subject><subject>United States</subject><subject>United States - epidemiology</subject><subject>Vaccination</subject><subject>Vaccines</subject><subject>Viruses</subject><issn>0149-2195</issn><issn>1545-861X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>ALSLI</sourceid><sourceid>M2R</sourceid><recordid>eNp9k91v0zAUxQMCsTJ45RFZQ0I8kGLH-XB4QVXHx6RKTGydeIsc57o1SuxiO526vx6nXadtqnAeLOX-zjk3N7pR9IbgMckyln3qums77roiSQmQp9GIZGkWs5z8fhaNMEnLOCFldhS9dO4PHg7FL6IjWrAkTRM6ejKaO0BGIr8EdC7VDVj0C9xKWe6N3aCLjRYbr3iLrpTtHbriQigN6LS3Si_QuYWF5gFB0tidh4U1aK-MHlz_YxVPnDNCcQ8NmpnrR7mXlguPTpUDHvpTGp1pybV3nwMlTNeBbvgQ4va9T5q1coNyGqrKewhfFVRd12t1s0VDa8FTCXAoRnOthuALH_LdR5TghL6KnkveOnh9ex9H829fL6c_4tnP72fTySwWaV6SmNS5pCnjEnDJmawbyXlNilrUNKWMNilOS8AZx6SUQPNaJhynUhSFxAnLZEGPoy8731Vfd9CIMC3L22plVcftpjJcVQ8rWi2rhVlXBGcFKzMSHE5uHaz524PzlYWVsd5VCSsYJTkpywB9eAR1ygloW67B9Fu0oAxnePB7t0MXvIVKaWlCrhjwalLkZVIUmOWBig9QC9AQmjQapAqvH_DjA3x4GuiUOCh4f0-wBN76pTNtv_3PB52FNc5ZkHfDI7jabkU1bEW134ogeHt_5Hf4fg3oPwWZDec</recordid><startdate>20231013</startdate><enddate>20231013</enddate><creator>Fleming-Dutra, Katherine E</creator><creator>Jones, Jefferson M</creator><creator>Roper, Lauren E</creator><creator>Prill, Mila M</creator><creator>Ortega-Sanchez, Ismael R</creator><creator>Moulia, Danielle L</creator><creator>Wallace, Megan</creator><creator>Godfrey, Monica</creator><creator>Broder, Karen R</creator><creator>Tepper, Naomi K</creator><creator>Brooks, Oliver</creator><creator>Sánchez, Pablo J</creator><creator>Kotton, Camille N</creator><creator>Mahon, Barbara E</creator><creator>Long, Sarah S</creator><creator>McMorrow, Meredith L</creator><general>U.S. Government Printing Office</general><general>U.S. Center for Disease Control</general><general>Centers for Disease Control and Prevention</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>0-V</scope><scope>3V.</scope><scope>4T-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>88F</scope><scope>88J</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M1Q</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>S0X</scope><scope>5PM</scope></search><sort><creationdate>20231013</creationdate><title>Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023</title><author>Fleming-Dutra, Katherine E ; Jones, Jefferson M ; Roper, Lauren E ; Prill, Mila M ; Ortega-Sanchez, Ismael R ; Moulia, Danielle L ; Wallace, Megan ; Godfrey, Monica ; Broder, Karen R ; Tepper, Naomi K ; Brooks, Oliver ; Sánchez, Pablo J ; Kotton, Camille N ; Mahon, Barbara E ; Long, Sarah S ; McMorrow, Meredith L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Advisory Committees</topic><topic>Communicable Diseases</topic><topic>COVID-19 vaccines</topic><topic>Disease prevention</topic><topic>Disease transmission</topic><topic>Diseases</topic><topic>Drug approval</topic><topic>Drug dosages</topic><topic>Economic impact</topic><topic>Epidemiology</topic><topic>FDA approval</topic><topic>Female</topic><topic>France</topic><topic>Full Report</topic><topic>Gestation</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Immunization</topic><topic>Infant</topic><topic>Infants</topic><topic>Pandemics</topic><topic>Pediatrics</topic><topic>Pharmaceutical industry</topic><topic>Preeclampsia</topic><topic>Pregnancy</topic><topic>Pregnant women</topic><topic>Premature birth</topic><topic>Prevention</topic><topic>Public health</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory Syncytial Virus Infections - epidemiology</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory Syncytial Virus Vaccines</topic><topic>Respiratory Syncytial Virus, Human</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Respiratory tract infection</topic><topic>Respiratory Tract Infections - epidemiology</topic><topic>Respiratory Tract Infections - prevention & control</topic><topic>Seasons</topic><topic>United Kingdom</topic><topic>United States</topic><topic>United States - epidemiology</topic><topic>Vaccination</topic><topic>Vaccines</topic><topic>Viruses</topic><toplevel>online_resources</toplevel><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Jones, Jefferson M</creatorcontrib><creatorcontrib>Roper, Lauren E</creatorcontrib><creatorcontrib>Prill, Mila M</creatorcontrib><creatorcontrib>Ortega-Sanchez, Ismael R</creatorcontrib><creatorcontrib>Moulia, Danielle L</creatorcontrib><creatorcontrib>Wallace, Megan</creatorcontrib><creatorcontrib>Godfrey, Monica</creatorcontrib><creatorcontrib>Broder, Karen R</creatorcontrib><creatorcontrib>Tepper, Naomi K</creatorcontrib><creatorcontrib>Brooks, Oliver</creatorcontrib><creatorcontrib>Sánchez, Pablo J</creatorcontrib><creatorcontrib>Kotton, Camille N</creatorcontrib><creatorcontrib>Mahon, Barbara E</creatorcontrib><creatorcontrib>Long, Sarah S</creatorcontrib><creatorcontrib>McMorrow, Meredith L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Database</collection><collection>ProQuest Agriculture & Environmental Science Database</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Military Database</collection><collection>ProQuest research library</collection><collection>Social Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>MMWR. Morbidity and mortality weekly report</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fleming-Dutra, Katherine E</au><au>Jones, Jefferson M</au><au>Roper, Lauren E</au><au>Prill, Mila M</au><au>Ortega-Sanchez, Ismael R</au><au>Moulia, Danielle L</au><au>Wallace, Megan</au><au>Godfrey, Monica</au><au>Broder, Karen R</au><au>Tepper, Naomi K</au><au>Brooks, Oliver</au><au>Sánchez, Pablo J</au><au>Kotton, Camille N</au><au>Mahon, Barbara E</au><au>Long, Sarah S</au><au>McMorrow, Meredith L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023</atitle><jtitle>MMWR. Morbidity and mortality weekly report</jtitle><addtitle>MMWR Morb Mortal Wkly Rep</addtitle><date>2023-10-13</date><risdate>2023</risdate><volume>72</volume><issue>41</issue><spage>1115</spage><epage>1122</epage><pages>1115-1122</pages><issn>0149-2195</issn><eissn>1545-861X</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>ObjectType-Instructional Material/Guideline-3</notes><notes>content type line 23</notes><abstract>Respiratory syncytial virus (RSV) is the leading cause of hospitalization among U.S. infants. Nirsevimab (Bevfortus, Sanofi and AstraZeneca) is recommended to prevent RSV-associated lower respiratory tract infection (LRTI) in infants. In August 2023, the Food and Drug Administration (FDA) approved RSVpreF vaccine (Abrysvo, Pfizer Inc.) for pregnant persons as a single dose during 32-36 completed gestational weeks (i.e., 32 weeks and zero days' through 36 weeks and 6 days' gestation) to prevent RSV-associated lower respiratory tract disease in infants aged <6 months. Since October 2021, CDC's Advisory Committee on Immunization Practices (ACIP) RSV Vaccines Pediatric/Maternal Work Group has reviewed RSV epidemiology and evidence regarding safety, efficacy, and potential economic impact of pediatric and maternal RSV prevention products, including RSVpreF vaccine. On September 22, 2023, ACIP and CDC recommended RSVpreF vaccine using seasonal administration (i.e., during September through end of January in most of the continental United States) for pregnant persons as a one-time dose at 32-36 weeks' gestation for prevention of RSV-associated LRTI in infants aged <6 months. Either maternal RSVpreF vaccination during pregnancy or nirsevimab administration to the infant is recommended to prevent RSV-associated LRTI among infants, but both are not needed for most infants. All infants should be protected against RSV-associated LRTI through use of one of these products.</abstract><cop>United States</cop><pub>U.S. Government Printing Office</pub><pmid>37824423</pmid><doi>10.15585/mmwr.mm7241e1</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2195 |
| ispartof | MMWR. Morbidity and mortality weekly report, 2023-10, Vol.72 (41), p.1115-1122 |
| issn | 0149-2195 1545-861X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10578951 |
| source | Open Access: PubMed Central; JSTOR Archival Journals and Primary Sources Collection; Social Science Premium Collection (Proquest) (PQ_SDU_P3) |
| subjects | Advisory Committees Communicable Diseases COVID-19 vaccines Disease prevention Disease transmission Diseases Drug approval Drug dosages Economic impact Epidemiology FDA approval Female France Full Report Gestation Hospitalization Humans Hypertension Immunization Infant Infants Pandemics Pediatrics Pharmaceutical industry Preeclampsia Pregnancy Pregnant women Premature birth Prevention Public health Respiratory syncytial virus Respiratory Syncytial Virus Infections - epidemiology Respiratory Syncytial Virus Infections - prevention & control Respiratory Syncytial Virus Vaccines Respiratory Syncytial Virus, Human Respiratory tract Respiratory tract diseases Respiratory tract infection Respiratory Tract Infections - epidemiology Respiratory Tract Infections - prevention & control Seasons United Kingdom United States United States - epidemiology Vaccination Vaccines Viruses |
| title | Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023 |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A19%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20the%20Pfizer%20Respiratory%20Syncytial%20Virus%20Vaccine%20During%20Pregnancy%20for%20the%20Prevention%20of%20Respiratory%20Syncytial%20Virus-Associated%20Lower%20Respiratory%20Tract%20Disease%20in%20Infants:%20Recommendations%20of%20the%20Advisory%20Committee%20on%20Immunization%20Practices%20-%20United%20States,%202023&rft.jtitle=MMWR.%20Morbidity%20and%20mortality%20weekly%20report&rft.au=Fleming-Dutra,%20Katherine%20E&rft.date=2023-10-13&rft.volume=72&rft.issue=41&rft.spage=1115&rft.epage=1122&rft.pages=1115-1122&rft.issn=0149-2195&rft.eissn=1545-861X&rft_id=info:doi/10.15585/mmwr.mm7241e1&rft_dat=%3Cgale_pubme%3EA769277086%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4691-1b6f348afe09a8fbdfaab17bcb34383d4049e05a019fe36bf2a04fc77f0285f73%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2878316199&rft_id=info:pmid/37824423&rft_galeid=A769277086&rfr_iscdi=true |